Zhitong Financial App News, China Biopharmaceutical (01177.HK) issued an announcement. The national Class 1 innovative drug TQB2102 “HER2 double epitope ADC” independently developed by the Group's subsidiary, Zhengda Tianqing Pharmaceutical Group Co., Ltd. (Zhengda Tianqing), announced two clinical data at the 2026 European Society of Medical Oncology (ESMO) annual meeting, and were selected for the conference selected as Proffered Paper (LBA) and Rapid Oral Report (Rapid Oral) respectively.

Disclaimer:Webull uses external vendor Google Translation Service for news translations where we endeavour to ensure these are correct, however, we recommend that you please double-check this information accordingly. Webull is not responsible for translation errors or issues.